PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1324364
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1324364
According to Stratistics MRC, the Global Modular Laboratory Automation Market is accounted for $3.89 billion in 2023 and is expected to reach $6.71 billion by 2030 growing at a CAGR of 8.1% during the forecast period. Modular Lab Automation is a type of laboratory automation process frequently used in drug discovery, diagnostics, genomics, etc. Any device, piece of software, or piece of equipment that requires little to no human interaction while increasing lab productivity and efficiency is referred to as "laboratory automation." Robots, conveyors, software, and other devices are all part of automation.
Faster and more effective procedures are constantly needed in laboratories, particularly those in the pharmaceutical, biotechnology, and clinical research industries. The ability to automate monotonous and time-consuming tasks is provided by modular laboratory automation, significantly boosting throughput and overall effectiveness of this market during the forecast period.
Equipment, software, and integration are frequently expensive up front when implementing modular laboratory automation systems. For smaller labs or those with tighter budgets, the initial cost can be a major barrier. Such factors limit market expansion.
Modular laboratory automation systems are now more adaptable, dependable, and economical thanks to technological advancements in robotics, sensor technologies, and integration capabilities. The range of applications for automation in different laboratory processes has increased as a result of these developments. Moreover, automation systems can also help increase data traceability and accuracy, boosting compliance and audit readiness.
Automation protocols and interfaces are frequently not standardised in the laboratory industry. As a result, there may be compatibility problems between various automation components, which could obstruct the smooth integration of automation systems. Moreover, compatibility problems and the need for customised solutions can also increase the time and cost of implementation.
The COVID-19 pandemic has sped up medical research and development while putting more pressure on pharmaceutical firms and clinical labs. Making sure a shorter TAT is achieved has gained importance as a result of the increased interest in microplate readers, automated liquid handling, and robots. On the other hand, the epidemic has led to lower spending on automation and technology, as well as lower revenues and margins for hospitals and health systems. This has an effect on the future market for modular laboratory automation.
The automated liquid handlers segment is expected to be the largest during the anticipated period. Laboratories that work with chemicals and biochemistry frequently employ liquid handlers. In laboratories, automated liquid handling robots assist with dispensing samples and other liquids. Automated liquid handlers reduce cycle times and increase precision. Additionally, liquid handlers can work with a variety of volumes, down to nanolitres, demonstrating their value in dispensing operations.
The clinical diagnostics segment is expected to witness lucrative growth during the forecast period. The ability of modular laboratory automation to optimise laboratory workflows, increase productivity, increase accuracy, and decrease the possibility of human error has led to its widespread use in clinical diagnostics. Additionally, modular automation can be used to automate different immunoassays and clinical chemistry tests, enabling laboratories to process a large number of tests quickly and with little user involvement.
Due to widespread adoption of cutting-edge technologies across all end-user segments, North America is anticipated to dominate the modular laboratory automation market. The market is predicted to be driven by investments in cutting-edge genomics, proteomics, and epigenetics research, a rise in the focus on environmental concerns, and the concentration of some of the biggest pharmaceutical and biotechnology companies in the world as well as academic institutions in the region.
The demand for lab automation solutions is expected to rise in the Asia-Pacific region, primarily as a result of the region's explosive growth in the pharmaceutical industry. The continuation of demographic and economic trends, new healthcare reforms, and the policies outlined in the government's five-year plan are all anticipated to fuel market expansion. Vendors of lab automation solutions now have new opportunities to increase their footprint thanks to the rapidly expanding market.
Some of the key players profiled in the Modular Laboratory Automation Market include: Agilent Technologies, Inc., Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Eppendorf AG, F. Hoffmann-La Roche Ltd., Honeywell International Inc., Hudson Robotics, Inc., PerkinElmer, Inc., QIAGEN N.V., Shimadzu Scientific Instruments, Siemens Healthineers, Synchron Lab Automation, Tecan Group Ltd. And Thermo Fisher Scientific, Inc.
In June 2022, MegaRobo Technologies Ltd announced the completion of a USD 300 million Series C fundraising round. MegaRobo would use the funds to continue its R&D investments, capacity growth, and global expansion. MegaRobo has offered the life sciences industry a comprehensive set of automation solutions. Ranging from benchtop workflow automation for simple workflows to a fully automated platform for complex workflows in large system journey applications, with plans to expand into the next-generation life sciences infrastructure system for R&D and AI drug development.
In May 2022, Global life science innovators MGI Tech Co. Ltd (MGI) and King Abdullah International Medical Research Center (KAIMRC) signed a Memorandum of Understanding (MOU) to form a strategic collaboration in the domains of genomic science and biotechnology. The MOU anticipates establishing a high-throughput sequencing center in KAIMRC, which may accommodate MGI's technology platforms, including DNBSEQ sequencing, laboratory automation, and bioinformatics products. Driven by MGI's proprietary DNBSEQ technology, the partnership will employ MGI's platform to improve genome sequencing and data quality across a wide range of applications.